.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Reducing the global onchocerciasis disease burden remains a top priority for public health initiatives in sub-Saharan Africa. Recent advances in mathematical modelling, specifically the EPIONCHO-IBM transmission model, allow researchers to simulate how mass drug administration (MDA) affects clinical outcomes. This study evaluates the long-term effectiveness of ivermectin on both cutaneous and ocular manifestations of Onchocerca volvulus.
The research team integrated a new morbidity sub-model into the stochastic EPIONCHO-IBM framework. This addition covers reversible sequelae, such as severe itch and reactive skin disease (RSD). Furthermore, it addresses irreversible conditions like skin atrophy, depigmentation, and visual impairment. By using historical data from West Africa and Nigeria, the model establishes a baseline for the onchocerciasis disease burden before interventions.
Simulations based on data from five African nations showed that annual ivermectin administration significantly reduces morbidity. However, the model suggests that while trends in infection and severe itch are well-captured, reductions in blindness and chronic skin disease may be slower than previously estimated. Consequently, these findings highlight the necessity of sustained intervention strategies to manage the onchocerciasis disease burden effectively.
Integrating morbidity outcomes into transmission dynamics provides a more comprehensive view of the onchocerciasis disease burden. This improved estimation helps health authorities optimize the cost-effectiveness of current programs. Moreover, it assists in identifying where alternative treatments might be required to reach elimination goals. In addition, these models serve as vital tools for policy makers to project the health impacts of different strategies.
Ivermectin primarily kills the microfilariae (larvae) of the parasite. This reduction in the larval population decreases skin and eye inflammation, thereby preventing new cases of blindness and severe skin disease.
No. While severe itch and certain reactive skin diseases are reversible, chronic conditions like skin atrophy, depigmentation, and established visual impairment or blindness are generally irreversible even with ivermectin treatment.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a substitute for professional healthcare. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A modelling study evaluating the impact of ivermectin on onchocerciasis-associated skin and ocular diseases using the EPIONCHO-IBM transmission framework....
6 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
